| Date Filed | Type | Description |
| 03/05/2014 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 03/05/2014 |
4
| Christmas Patrick J. (General Counsel) has filed a Form 4 on K-V Pharmaceutical Co |
| 03/05/2014 |
4
| Nielson Steven (Director) has filed a Form 4 on K-V Pharmaceutical Co |
| 03/05/2014 |
4
| McInnis Joe (Director) has filed a Form 4 on K-V Pharmaceutical Co |
| 03/05/2014 |
4
| Vergis Janet S. (Director) has filed a Form 4 on K-V Pharmaceutical Co |
| 03/05/2014 |
4
| MCHUGH THOMAS S (CFO) has filed a Form 4 on K-V Pharmaceutical Co |
| 03/05/2014 |
4
| Goldfarb James M. (Director) has filed a Form 4 on K-V Pharmaceutical Co |
| 03/05/2014 |
4
| Norden Gregory (Director) has filed a Form 4 on K-V Pharmaceutical Co |
| 03/05/2014 |
4
| DIVIS GREG J (CEO and President) has filed a Form 4 on K-V Pharmaceutical Co |
| 11/20/2013 |
4
| Silver Point Capital L.P. (10% Owner) has filed a Form 4 on K-V Pharmaceutical Co|
Txns:
| Bought 25,000 shares
@ $46.5, valued at
$1.2M
|
|
| 11/15/2013 |
4
| Silver Point Capital L.P. (10% Owner) has filed a Form 4 on K-V Pharmaceutical Co|
Txns:
| Bought 57,162 shares
@ $42.75, valued at
$2.4M
Bought 50,000 shares
@ $44.5, valued at
$2.2M
|
|
| 11/06/2013 |
8-K
| Quarterly results |
| 11/01/2013 |
4
| Vergis Janet S. (Director) has filed a Form 4 on K-V Pharmaceutical Co|
Txns:
| Granted 15,000 options to buy
@ $28.8, valued at
$432k
Granted 5,000 options to buy
@ $32, valued at
$160k
Granted 3,751 restricted stock units
@ $0 |
|
| 11/01/2013 |
3
| Vergis Janet S. (Director) has filed a Form 3 on K-V Pharmaceutical Co |
| 10/25/2013 |
4
| MAHADY JOSEPH M (Director) has filed a Form 4 on K-V Pharmaceutical Co |
| 10/23/2013 |
4
| Goldfarb James M. (Director) has filed a Form 4 on K-V Pharmaceutical Co|
Txns:
| Granted 15,000 options to buy
@ $28.8, valued at
$432k
Granted 5,000 options to buy
@ $32, valued at
$160k
Granted 3,751 restricted stock units
@ $0 |
|
| 10/23/2013 |
3
| Goldfarb James M. (Director) has filed a Form 3 on K-V Pharmaceutical Co |
| 10/23/2013 |
4
| Norden Gregory (Director) has filed a Form 4 on K-V Pharmaceutical Co|
Txns:
| Granted 15,000 options to buy
@ $28.8, valued at
$432k
Granted 5,000 options to buy
@ $32, valued at
$160k
Granted 3,751 restricted stock units
@ $0 |
|
| 10/23/2013 |
3
| Norden Gregory (Director) has filed a Form 3 on K-V Pharmaceutical Co |
| 10/18/2013 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/15/2013 |
3
| Haron Eric (Director) has filed a Form 3 on K-V Pharmaceutical Co |
| 10/15/2013 |
3
| McInnis Joe (Director) has filed a Form 3 on K-V Pharmaceutical Co |
| 10/15/2013 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)] |
| 10/11/2013 |
3
| Form 3 - Initial statement of beneficial ownership of securities |
| 10/04/2013 |
4
| Christmas Patrick J. (General Counsel) has filed a Form 4 on K-V Pharmaceutical Co|
Txns:
| Granted 86,806 restricted stock units
@ $0
Granted 40,327 options to buy
@ $20, valued at
$806.5k
|
|
| 10/04/2013 |
3
| Siegel Jonathan B. (Director) has filed a Form 3 on K-V Pharmaceutical Co |
| 10/04/2013 |
4
| MCHUGH THOMAS S (CFO) has filed a Form 4 on K-V Pharmaceutical Co|
Txns:
| Granted 86,806 restricted stock units
@ $0
Granted 40,327 options to buy
@ $20, valued at
$806.5k
|
|
| 10/04/2013 |
4
| DIVIS GREG J (CEO and President) has filed a Form 4 on K-V Pharmaceutical Co|
Txns:
| Granted 173,611 restricted stock units
@ $0
Granted 80,653 options to buy
@ $20, valued at
$1.6M
|
|
| 10/04/2013 |
8-K
| Appointed a new director|
Docs:
|
"Non-Employee Director Compensation Policy",
"Form of Option Award Agreement",
"Form of Equity Bonus Agreement",
"KV Pharmaceutical Company Appoints Former Wyeth Pharmaceuticals President, Joe Mahady to Chairman of the Board ST. LOUIS, Oct. 3, 2013 – K-V Pharmaceutical Company today announced the appointment of Joseph M. Mahady as Chairman of its Board of Directors. Previously, Mahady served as Senior Vice President of Wyeth, LLC, and President of Wyeth Pharmaceuticals, Inc., where he led the company’s $20 billion global pharmaceutical business. During his tenure, he oversaw the successful launch of more than 30 products in multiple therapeutic areas. Mahady has held various board positions, including Immunex, Albemarle, EKR Therapeutics, Discovery Labs and Cortendo AB. “Joe’s extensive knowledge and expertise in women’s healthcare will play a critical role in establishing a renewed focus at the compa..." |
|
| 09/27/2013 |
4
| Stancic Ana (Director) has filed a Form 4 on K-V Pharmaceutical Co|
Txns:
| Disposed of 10,000 options to buy
@ $1.62, valued at
$16.2k
Disposed of 7,500 options to buy
@ $1.14, valued at
$8.6k
Disposed of 20,000 options to buy
@ $1.49, valued at
$29.8k
Disposed of 20,000 options to buy
@ $0.94, valued at
$18.8k
|
|
| 09/27/2013 |
4
| BALDINI ROBERT E (Director) has filed a Form 4 on K-V Pharmaceutical Co |
| 09/27/2013 |
4
| Silver Point Capital L.P. (10% Owner) has filed a Form 4 on K-V Pharmaceutical Co|
Txns:
| Sold 199,000 shares
@ $40, valued at
$8M
|
|
| 09/26/2013 |
4
| Dow Mark A. (Director) has filed a Form 4 on K-V Pharmaceutical Co |
| 09/26/2013 |
4
| BENTLEY GREGORY SMITH (Director) has filed a Form 4 on K-V Pharmaceutical Co |
|